{"nct_id":"NCT04907227","title":"Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension","status":"TERMINATED","status_verified_date":"2024-06","start_date":"2020-09-23","start_date_type":"ACTUAL","primary_completion_date":"2022-08-03","primary_completion_date_type":"ACTUAL","completion_date":"2023-07-18","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["MRK"]}